Sarkar et al. showed that in the USA, the use of long-acting insulin accounts for 74.8% of the T2DM patients who received insulin therapy compared to 16.5% in terms of rapid-acting insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.